Depiction of Prostate Cancer Treatment Alternatives in Greece

October 13, 2009 updated by: AstraZeneca

A retrospective, registry analysis of the socio-economic and demographic characteristics of patients suffering from locally advanced or metastatic prostate cancer, as well as the depiction of the therapeutic algorithms followed in the Greek clinical practice.

  • Target Group: Patients with locally advanced or metastatic prostate cancer.
  • The first 10 consecutive patients records that meet the entry criteria.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Anticipated)

310

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Greece
      • Athens, Greece
        • Research Site
      • Karditsa, Greece
        • Research Site
      • Serres, Greece
        • Research Site
      • Xsanthi, Greece
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Sampling Method

Probability Sample

Study Population

Target Group: Patients diagnosed with Locally advanced or Metastatic Prostate Cancer

Description

Inclusion Criteria:

  • Patients diagnosed with Locally advanced or Metastatic Prostate Cancer after 2002.
  • Patients that received Hormonal therapy.

Exclusion Criteria:

  • Males that are aged less than 18 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage of patients treated by each treatment alternative.
Time Frame: Between 2002 - 2008
Between 2002 - 2008

Secondary Outcome Measures

Outcome Measure
Time Frame
To depict sociodemographic characteristics and comorbidities.
Time Frame: Between 2002 - 2008
Between 2002 - 2008

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

  • Study Director: Panagiotis Pontikis, MD, AstraZeneca Greece

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2008

Study Completion (Actual)

March 1, 2009

Study Registration Dates

First Submitted

August 8, 2008

First Submitted That Met QC Criteria

August 11, 2008

First Posted (Estimate)

August 12, 2008

Study Record Updates

Last Update Posted (Estimate)

October 14, 2009

Last Update Submitted That Met QC Criteria

October 13, 2009

Last Verified

October 1, 2009

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIS-OGR-DUM-2007/1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Locally Advanced or Metastatic Prostate Cancer.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe